Levofloxacin (hydrochloride)

• UNSPSC Description:

  Levofloxacin ((-)-Ofloxacin) hydrochloride is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride inhibits the DNA gyrase and topoisomerase IV. Levofloxacin hydrochloride can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrochloride shows anti-orthopoxvirus activity[1][2][3][4][5].

• Target Antigen:

  Antibiotic; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/levofloxacin-hydrochloride.html

• Purity:

  98.0

• Solubility:

  H2O : 20 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  [H]Cl.O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O

• Molecular Weight:

  397.83

• References & Citations:

  [1]Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.|[2]Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.|[3]Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.|[4]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. |[5]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.Emerg Microbes Infect. 2024 Dec;13(1):2321981.|ACS Infect Dis. 2024 Apr 12;10(4):1327-1338.|Antibiotics (Basel). 2022, 11(2), 192.|Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01921-20.|bioRxiv. 2024 May 10.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Chin J Traumatol. 2024 Jul 3:S1008-1275(24)00075-0.|Clin Chem. 2019 Dec;65(12):1522-1531. |PLoS One. 2024 Apr 18;19(4):e0298577.|Results Chem. 2024 Oct.|Nat Commun. 2022 Mar 2;13(1):1116.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  177325-13-2